Posted by Michael Wonder on 18 Feb 2021
HLS Therapeutics provides update on private and public payer reimbursement for Vascepa
16 February 2021 - Active negotiations have also begun with the pan-Canadian Pharmaceutical Alliance for reimbursement of Vascepa by publicly funded health plans.
HLS Therapeutics expects that by the end of February 2021, private payer health plans covering more than 80% of the privately insured lives in Canada will have agreed to provide reimbursement for Vascepa.
